Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis
Panaccione R., Chan-Diehl F., Baygani S., Fisher DA., Moses RE., Siegmund B., Walsh A., Kobayashi T., Dulai PS., Travis S.
Lay Summary: Associations between fecal calprotectin and C-reactive protein biomarker improvement for patients with moderately to severely active ulcerative colitis treated with mirikizumab were assessed. Results indicate that biomarker analyses may provide a noninvasive monitoring strategy for use in clinical practice.